R.I.P.: Merck and Endocyte yank vintafolide app

Now that the ovarian cancer drug vintafolide has crumbled in Phase III, Merck ($MRK) and its partner Endocyte ($ECYT) have pulled their conditional marketing application in Europe and are moving to close down the study. Enrollment was halted a couple of weeks ago after the monitoring group concluded that it was futile to proceed after missing its mark on progression-free survival. European regulators had supported a conditional approval back in March, but that's all ancient history now. The companies plan on waiting for Phase IIb results for non-small cell lung cancer before they make a final determination on the drug's fate. Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.